SK107495A3 - Use of lamotrigine for treating aids-related neural disorders - Google Patents

Use of lamotrigine for treating aids-related neural disorders Download PDF

Info

Publication number
SK107495A3
SK107495A3 SK1074-95A SK107495A SK107495A3 SK 107495 A3 SK107495 A3 SK 107495A3 SK 107495 A SK107495 A SK 107495A SK 107495 A3 SK107495 A3 SK 107495A3
Authority
SK
Slovakia
Prior art keywords
lamotrigine
pharmaceutically acceptable
aids
treatment
disorders
Prior art date
Application number
SK1074-95A
Other languages
English (en)
Slovak (sk)
Inventor
Anne Bousseau
Adam Doble
Erik Louvel
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of SK107495A3 publication Critical patent/SK107495A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SK1074-95A 1993-03-05 1994-02-25 Use of lamotrigine for treating aids-related neural disorders SK107495A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9302568A FR2702148B1 (fr) 1993-03-05 1993-03-05 Application d'anticonvulsivants dans le traitement du neuro-sida.
PCT/FR1994/000210 WO1994020108A1 (fr) 1993-03-05 1994-02-25 Application de la lamotrigine dans le traitement du neuro-sida

Publications (1)

Publication Number Publication Date
SK107495A3 true SK107495A3 (en) 1996-06-05

Family

ID=9444690

Family Applications (3)

Application Number Title Priority Date Filing Date
SK1075-95A SK107595A3 (en) 1993-03-05 1994-02-25 Use of anticonvulsive agents for treating aids-related neural disorders
SK1076-95A SK279659B6 (sk) 1993-03-05 1994-02-25 Použitie riluzolu
SK1074-95A SK107495A3 (en) 1993-03-05 1994-02-25 Use of lamotrigine for treating aids-related neural disorders

Family Applications Before (2)

Application Number Title Priority Date Filing Date
SK1075-95A SK107595A3 (en) 1993-03-05 1994-02-25 Use of anticonvulsive agents for treating aids-related neural disorders
SK1076-95A SK279659B6 (sk) 1993-03-05 1994-02-25 Použitie riluzolu

Country Status (23)

Country Link
US (2) US5629312A (ru)
EP (3) EP0687177B1 (ru)
JP (3) JP3578174B2 (ru)
KR (3) KR100318168B1 (ru)
AT (2) ATE201597T1 (ru)
AU (3) AU6143894A (ru)
CA (3) CA2154572C (ru)
CZ (3) CZ285339B6 (ru)
DE (2) DE69427344T2 (ru)
DK (2) DK0687176T3 (ru)
ES (2) ES2157252T3 (ru)
FR (1) FR2702148B1 (ru)
GR (2) GR3022356T3 (ru)
HU (3) HUT73434A (ru)
IL (3) IL108845A0 (ru)
NO (3) NO953371L (ru)
PL (3) PL310476A1 (ru)
PT (1) PT687176E (ru)
RU (1) RU2157205C2 (ru)
SK (3) SK107595A3 (ru)
UA (1) UA41355C2 (ru)
WO (3) WO1994020108A1 (ru)
ZA (2) ZA941530B (ru)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5866597A (en) * 1993-03-19 1999-02-02 Glaxo Wellcome Inc. Use of triazine compounds for the treatment of memory and learning disorders
GB9424766D0 (en) * 1994-12-07 1995-02-08 Wellcome Found Pharmaceutical composition
GB9512854D0 (en) * 1995-06-23 1995-08-23 Wellcome Found Novel formulation
DE19603984A1 (de) * 1996-02-05 1997-08-07 Bayer Ag Granulate von Triazinen
US20020022056A1 (en) 1997-02-14 2002-02-21 Burkhard Schlutermann Oxacarbazepine film-coated tablets
CO4920215A1 (es) * 1997-02-14 2000-05-29 Novartis Ag Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones
US5922746A (en) * 1997-03-27 1999-07-13 Allergan Inhibition of noninactivating Na channels of mammalian optic nerve as a means of preventing optic nerve degeneration associated with glaucoma
GB9721497D0 (en) 1997-10-09 1997-12-10 Ciba Geigy Ag Organic compounds
FR2774592B1 (fr) * 1998-02-06 2000-03-17 Rhone Poulenc Rorer Sa Application du 2-amino-6-trifluoromethoxybenzothiazole pour la prevention ou le traitement des dysfonctionnements du cervelet
FR2774908B1 (fr) * 1998-02-17 2000-06-23 Centre Nat Rech Scient Utilisation d'inhibiteur de la liberation du glutamate dans le traitement de l'ischemie retinienne
FR2787028B1 (fr) * 1998-12-15 2002-10-18 Aventis Pharma Sa Utilisation du riluzole dans le traitement des traumatismes acoustiques
EP1173175A1 (en) * 1999-04-29 2002-01-23 Centre National De La Recherche Scientifique (Cnrs) A method for the prevention of ischemic spinal cord injury caused by aortic crossclamping
US7479498B2 (en) * 1999-08-23 2009-01-20 Phoenix Biosciences, Inc. Treatments for viral infections
GB9925962D0 (en) * 1999-11-02 1999-12-29 Novartis Ag Organic compounds
FR2801217B1 (fr) * 1999-11-24 2002-12-06 Aventis Pharma Sa Association de riluzole et de gabapentine et son utilisation comme medicament
GB9930058D0 (en) 1999-12-20 2000-02-09 Novartis Ag Organic compounds
US6207179B1 (en) * 2000-05-18 2001-03-27 Phoenix Scientific, Inc. Parasiticidal formulation for animals and a method of making this formulation
CA2471666C (en) 2004-06-18 2009-10-13 Apotex Pharmachem Inc. An improved process for the preparation of oxcarbazepine and related intermediates
DK2201963T3 (en) * 2005-04-05 2016-02-15 Univ Yale Glutamate-modulating agents in the treatment of mental disorders
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
FR2910811B1 (fr) * 2007-01-03 2009-07-10 Ass Pour Le Dev De La Biothera Utilisation du riluzole et de ses derives pour fabriquer de nouveaux medicaments
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
FR2957077B1 (fr) * 2010-03-02 2012-04-13 Univ Dauvergne Clermont I Utilisation du riluzole pour traiter ou prevenir les effets indesirables d'agents anti-cancereux
CA2967662A1 (en) * 2014-11-21 2016-05-26 Biohaven Pharmaceutical Holding Company Ltd. Sublingual formulation of riluzole
MX2023009844A (es) * 2021-02-24 2023-11-24 Valvoline Licensing & Intellectual Property LLC Limpiador espumante de serpentín del evaporador.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4431641A (en) * 1980-10-17 1984-02-14 Ciba-Geigy Corporation Pharmaceutical compositions having antiepileptic and antineuralgic action
FR2492258A1 (fr) * 1980-10-17 1982-04-23 Pharmindustrie Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole
GB8613183D0 (en) * 1986-05-30 1986-07-02 Wellcome Found Triazine salt
US4826860A (en) * 1987-03-16 1989-05-02 Warner-Lambert Company Substituted 2-aminobenzothiazoles and derivatives useful as cerebrovascular agents
US4918090A (en) * 1988-01-25 1990-04-17 Warner-Lambert Company Substituted 2-aminbenzothiazoles and derivatives useful as cerebrovascular agents
EP0435826A1 (de) * 1989-12-27 1991-07-03 Ciba-Geigy Ag Intravenöse Lösungen für Status Epilepticus
US5326570A (en) * 1991-07-23 1994-07-05 Pharmavene, Inc. Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
FR2688138B1 (fr) * 1992-03-06 1995-05-05 Rhone Poulenc Rorer Sa Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la sclerose laterale amyotrophique.
JPH07308499A (ja) * 1994-05-20 1995-11-28 Brother Ind Ltd 衣類乾燥機

Also Published As

Publication number Publication date
ZA941525B (en) 1994-11-09
AU675118B2 (en) 1997-01-23
AU6143894A (en) 1994-09-26
DE69401577T2 (de) 1997-05-15
CA2154571A1 (fr) 1994-09-15
WO1994020103A1 (fr) 1994-09-15
US5624945A (en) 1997-04-29
FR2702148A1 (fr) 1994-09-09
CZ226195A3 (en) 1995-12-13
NO953372D0 (no) 1995-08-28
JPH08507507A (ja) 1996-08-13
NO307687B1 (no) 2000-05-15
HU217132B (hu) 1999-11-29
DE69427344T2 (de) 2002-04-25
HUT73433A (en) 1996-07-29
SK107595A3 (en) 1996-06-05
CZ225995A3 (en) 1995-12-13
KR960700723A (ko) 1996-02-24
CA2154572C (fr) 2006-06-06
PL310474A1 (en) 1995-12-11
KR960700716A (ko) 1996-02-24
EP0687179A1 (fr) 1995-12-20
CA2154572A1 (fr) 1994-09-15
DK0687177T3 (da) 1997-02-10
US5629312A (en) 1997-05-13
KR960700721A (ko) 1996-02-24
ES2096455T3 (es) 1997-03-01
PL310476A1 (en) 1995-12-11
SK279659B6 (sk) 1999-02-11
JP3578174B2 (ja) 2004-10-20
PL310475A1 (en) 1995-12-11
ATE201597T1 (de) 2001-06-15
IL108845A0 (en) 1994-06-24
PT687176E (pt) 2001-09-28
RU2157205C2 (ru) 2000-10-10
CZ285339B6 (cs) 1999-07-14
NO953371D0 (no) 1995-08-28
AU6143794A (en) 1994-09-26
ATE147981T1 (de) 1997-02-15
JPH08507509A (ja) 1996-08-13
DE69427344D1 (de) 2001-07-05
GR3022356T3 (en) 1997-04-30
CA2154573A1 (fr) 1994-09-15
HU9502585D0 (en) 1995-11-28
JPH08507508A (ja) 1996-08-13
ES2157252T3 (es) 2001-08-16
NO953372L (no) 1995-08-28
EP0687176B1 (fr) 2001-05-30
AU675119B2 (en) 1997-01-23
SK107695A3 (en) 1996-06-05
NO953371L (no) 1995-08-28
UA41355C2 (ru) 2001-09-17
IL108844A0 (en) 1994-06-24
HU9502583D0 (en) 1995-11-28
WO1994020108A1 (fr) 1994-09-15
AU6143994A (en) 1994-09-26
HUT73434A (en) 1996-07-29
ZA941530B (en) 1994-10-06
NO953370D0 (no) 1995-08-28
DK0687176T3 (da) 2001-07-30
HU9502584D0 (en) 1995-11-28
IL108844A (en) 1998-01-04
CZ284423B6 (cs) 1998-11-11
EP0687177A1 (fr) 1995-12-20
DE69401577D1 (de) 1997-03-06
FR2702148B1 (fr) 1995-04-07
CZ226095A3 (en) 1995-12-13
GR3035957T3 (en) 2001-08-31
EP0687177B1 (fr) 1997-01-22
KR100318168B1 (ko) 2002-06-20
IL108846A0 (en) 1994-06-24
EP0687176A1 (fr) 1995-12-20
WO1994020110A1 (fr) 1994-09-15
NO953370L (no) 1995-08-28

Similar Documents

Publication Publication Date Title
SK107495A3 (en) Use of lamotrigine for treating aids-related neural disorders
DE69431568T2 (de) Inhibierung der migration und proliferation glatter muskeln mit hydroxycarbazolverbindungen
US5674885A (en) Application of riluzole in the treatment of parkinson's disease and parkinsonian syndromes
DE60103556T3 (de) Zusammensetzungen zur behandlung von fettleibigkeit, welche antagonisten der cb1-rezeptoren und sibutramine enthalten
CZ212094A3 (en) The use of 2-amino-6-trifluoromethoxybenzothiazole for obtaining a medicament determined for treating diseases of motor neuron
US6258807B1 (en) Method for treating pain
JP3585045B2 (ja) ミトコンドリア疾病の処置におけるリルゾールの適用
EP1420782B1 (en) Use of nefiracetam for treating post-stroke neurodegeneration
EP0013252B1 (de) Mittel zur Senkung der Herzfrequenz
DE60307049T2 (de) Verwendung von Piperazin- Phenothiazin- Derivaten zur Herstellung eines Arzneimittels mit neuroprotektiven und/oder neurotropischen Wirkungen auf das ZNS und/oder PNS
DE60034249T2 (de) Kombination enthaltend cyamemazine und ein atypisches neuroleptikum
EP1307195A2 (de) Cilansetron enthaltende arzneimittel zur behandlung nicht-obstipativer männlicher ibs-patienten
DE3532036A1 (de) Pharmazeutische zubereitung zur behandlung des bluthochdrucks
US5656647A (en) Application of riluzole for promoting restoration following radiation
WO2003061654A1 (de) Pramipexol zur behandlung von hiv demenz
JPH02300125A (ja) 抗腫瘍剤